Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Earnings for Longboard Pharmaceuticals, Inc. (LBPH)
Earnings in 2023 (TTM): $-54,422,000
According to Longboard Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-54,422,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Longboard Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-54,422,000 | $-54,422,000 |
| 2022 | $-43,945,000 | $-43,092,000 |
| 2021 | $-27,797,000 | $-27,733,000 |
| 2020 | $-14,400,000 | $-14,400,000 |